Promentis Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
Promentis Pharmaceuticals General Information
Description
Developer of medical therapies designed to treat central nervous system disorders. The company's therapies are focused on activating a target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders, enabling healthcare practitioners to treat various psychiatric disorders.
Contact Information
Website
www.promentispharma.comCorporate Office
- 826 North Plankinton Avenue
- Suite 400
- Milwaukee, WI 53203
- United States
Corporate Office
- 826 North Plankinton Avenue
- Suite 400
- Milwaukee, WI 53203
- United States
Promentis Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | 01-Mar-2026 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 01-Nov-2020 | Completed | Generating Revenue | |||
| 9. Debt - General | 10-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series C) | 04-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series C) | 22-Sep-2017 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 01-Jan-2015 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 31-Dec-2013 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 28-Sep-2012 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 25-Feb-2010 | $1.95M | $2.2M | Completed | Startup | |
| 2. Debt - General | 11-Feb-2010 | $250K | $250K | Completed | Startup |
Promentis Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 2,224,536 | $0.001000 | 8% | $0.88 | $0.88 | 1x | $0.88 | 5.13% |
Promentis Pharmaceuticals Comparisons
Industry
Financing
Details
Promentis Pharmaceuticals Competitors (73)
One of Promentis Pharmaceuticals’s 73 competitors is Curemark, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Curemark | Venture Capital-Backed | New York, NY | ||||
| Lucid Psycheceuticals | Corporate Backed or Acquired | Toronto, Canada | ||||
| Astrocyte Pharma | Venture Capital-Backed | Groton, CT | ||||
| Aptinyx | Formerly VC-backed | Evanston, IL | ||||
| Supernus | Formerly VC-backed | Rockville, MD |
Promentis Pharmaceuticals Patents
Promentis Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20150344419-A1 | Propionic acids, propionic acid esters, and related compounds | Active | 30-May-2014 | ||
| US-9193681-B1 | Propionic acids, propionic acid esters, and related compounds | Inactive | 30-May-2014 | ||
| US-20150133544-A1 | Ethyl (2r)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof | Active | 08-Nov-2013 | ||
| US-9012674-B1 | Ethyl (2r)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof | Active | 08-Nov-2013 | ||
| AU-2014346591-A1 | Substituted n-acetyl-l-cysteine derivatives and related compounds | Active | 08-Nov-2013 | C07C327/34 |
Promentis Pharmaceuticals Signals
Promentis Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Michael J. Fox Foundation | Limited Partner | |||
| National Institute of Mental Health | Government |
Promentis Pharmaceuticals FAQs
-
When was Promentis Pharmaceuticals founded?
Promentis Pharmaceuticals was founded in 2007.
-
Where is Promentis Pharmaceuticals headquartered?
Promentis Pharmaceuticals is headquartered in Milwaukee, WI.
-
What is the size of Promentis Pharmaceuticals?
Promentis Pharmaceuticals has 5 total employees.
-
What industry is Promentis Pharmaceuticals in?
Promentis Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Promentis Pharmaceuticals a private or public company?
Promentis Pharmaceuticals is a Private company.
-
What is Promentis Pharmaceuticals’s current revenue?
The current revenue for Promentis Pharmaceuticals is .
-
How much funding has Promentis Pharmaceuticals raised over time?
Promentis Pharmaceuticals has raised $40.3M.
-
Who are Promentis Pharmaceuticals’s investors?
Aisling Capital, F-Prime, OrbiMed, Michael J. Fox Foundation, and National Institute of Mental Health are 5 of 7 investors who have invested in Promentis Pharmaceuticals.
-
Who are Promentis Pharmaceuticals’s competitors?
Curemark, Lucid Psycheceuticals, Astrocyte Pharma, Aptinyx, and Supernus are some of the 73 competitors of Promentis Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process